HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pre-treatment of donor with 1-deamino-8-d-arginine vasopressin could alleviate early failure of porcine xenograft in a cobra venom factor treated canine recipient.

AbstractOBJECTIVE:
Unlike cardiac or renal xenotransplants, the depletion of complement using cobra venom factor (CVF) does not improve pulmonary xenograft survival. Several cases suggest that the swine von Willebrand factor (vWF) may play a major role in presenting a different pathogenesis of pulmonary xenograft dysfunction from other organs. To evaluate the role of vWF and the complement system in mediating hyperacute vascular injury of pulmonary xenografts and elucidate pathogenesis of the injury, we performed swine-to-canine orthotropic single lung xenotransplantation after pre-treatment of 1-deamino-8-d-arginine vasopressin (DDAVP) and CVF.
METHODS:
We set up three groups for lung xenotransplantation: group I served as the control group; group II, recipients pre-treated with CVF; group III, donors pre-treated with DDAVP (9 mg/kg, 3 days)/recipients pre-treated with CVF (60 u/kg). Hemodynamic data, coagulation and complement system parameters, and grafted lung pathologies were examined serially for 3h after transplantation.
RESULTS:
DDAVP infusion reduced the vWF content in swine lung tissue in vivo (7.7+/-2.4 AU/mg vs 16.0+/-5.6 AU/mg, P < 0.0001). Infusion of CVF 24 h prior to transplantation effectively depleted the recipient's serum C3 and complement hemolytic activity below the detectable range. Regardless of the use of CVF, both groups I and II transplanted with unmodified grafts showed an immediate drop in leukocytes and platelet counts after transplantation. However, in group III, in recipients transplanted with DDAVP pre-treated swine lung, the platelet count did not decrease after transplantation (P = 0.0295). The decrease of plasma antithrombin and fibrinogen tended to be attenuated in group III. Light microscopic examination revealed extensive vascular thromboses in both capillary and larger vessels, as well as early pulmonary parenchymal damage in groups I and II, but were rarely observed in group III.
CONCLUSIONS:
Complement inhibition alone was not enough to alleviate intravascular thrombosis, the main pathology in pulmonary xenotransplantation. Pre-infusion of DDAVP to the donor animal was effective in preventing platelet sequestration and attenuated intravascular thrombosis. It is suggested that the strategies targeting vWF would be promising for successful pulmonary xenotransplantation.
AuthorsHee Jung Kang, Gene Lee, Ji Yeon Kim, Seung Hee Lee, Hyun Cho Wi, Pil Gyu Hwang, Doo Hyun Chung, Young Tae Kim
JournalEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (Eur J Cardiothorac Surg) Vol. 28 Issue 1 Pg. 149-56 (Jul 2005) ISSN: 1010-7940 [Print] Germany
PMID15982598 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Complement C3
  • Complement Inactivator Proteins
  • Elapid Venoms
  • cobra venom factor
  • von Willebrand Factor
  • Deamino Arginine Vasopressin
Topics
  • Animals
  • Blood Coagulation (drug effects)
  • Complement C3 (drug effects, metabolism)
  • Complement Hemolytic Activity Assay
  • Complement Inactivator Proteins (pharmacology)
  • Deamino Arginine Vasopressin (pharmacology)
  • Elapid Venoms (pharmacology)
  • Graft Rejection (immunology)
  • Leukocyte Count
  • Lung (immunology)
  • Lung Transplantation (immunology, methods)
  • Platelet Count
  • Pulmonary Circulation (drug effects)
  • Swine
  • Transplantation, Heterologous (immunology, methods)
  • Vascular Resistance (drug effects)
  • von Willebrand Factor (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: